ZYLOX-TB Medical Technology Co., Ltd. reported interim revenue of RMB 632.04 million for the six months ended 30 June 2026, up 31.1% from the prior-year period. Gross profit rose 35.2% to RMB 463.89 million, lifting gross margin to 73.4% (H1 2025: 71.2%) on the back of manufacturing efficiencies, supply-chain optimisation and a richer mix of high-margin products.

Period profit attributable to shareholders advanced 47.8% year-on-year to RMB 179.11 million. Excluding RMB 9.70 million in share-based compensation, adjusted net profit increased 43.7% to RMB 188.81 million.

Segment performance remained strong. Neurovascular interventional revenue grew 20.2% to RMB 365.96 million, representing 57.9% of total product sales, supported by nationwide roll-out of the Falco Embolization Assist Stent and sustained demand for Kylin Flow Diverter and SilverSnake catheters. Peripheral vascular interventional revenue rose 40.0% to RMB 246.92 million, fuelled by the UltraFree Drug-Coated PTA Balloon, Phoenix coil systems, Swan RFA Catheter and new launches such as Eagle Aspiration System and ZENFLOW Pufferfish Scoring Balloon Catheter. Revenue outside mainland China reached RMB 70.64 million, a 349.3% surge, now spanning 70 overseas markets.

Operating expenses remained contained relative to top-line expansion. Selling and distribution costs rose to RMB 115.09 million, or 18.2% of revenue (H1 2025: 17.7%), reflecting broader global marketing activities and integration of newly acquired German subsidiary optimed. R&D expenditure fell 12.5% year-on-year to RMB 106.37 million after project reprioritisation, while administrative expenses increased 15.5% to RMB 64.55 million; both ratios edged lower against revenue.

Total assets reached RMB 3.73 billion at period-end, up from RMB 3.57 billion as at 31 December 2025. Cash, term deposits and fair-value financial assets totalled RMB 2.39 billion, providing ample liquidity despite a shift in term-deposit allocation. Net current assets stood at RMB 1.44 billion. Borrowings increased to RMB 111.37 million following the consolidation of optimed, pushing the gearing ratio to 4.77% (31 December 2025: 1.97%).

The Board declared no interim dividend.

Management outlined priorities of accelerating global market penetration, advancing a 144-strong product pipeline—69 already launched in China—and enhancing operational efficiency to mitigate pricing pressures from centralised procurement schemes.